Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open Label, Single Arm, Multicenter Study of LioCyx in Subjects With Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma Post Liver Transplantation

Next Previous
X
Search
Trial Profile

A Phase I/II, Open Label, Single Arm, Multicenter Study of LioCyx in Subjects With Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma Post Liver Transplantation

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HBV-specific-TCR-redirected-T-cell-therapy-Lion-TCR (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Lion TCR

    • Most Recent Events

    • 27 Jun 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 23 Aug 2018 New trial record
    • 19 Aug 2018 According to a Lion TCR media release, the company received approval from Health Sciences Authority (HSA), Singapore, for this trial of LioCyx.Patients recruitment will begin with National University Hospital (NUH), Singapore. Lion TCR is in the midst of including more medical centres in Singapore and China into the trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top